Health Condition 1: C068- Malignant neoplasm of overlappingsites of other and unspecified parts of mouth
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Dr Manjula M
Eligibility
Inclusion criteria
Inclusion criteria: Group I Patients with histopathologically confirmed OSCC Any stage and grade No prior therapy surgery chemotherapy or radiotherapy Group II Histologically confirmed oral leukoplakia Aged 18 years and above Clinically and histologically confirmed as oral leukoplakia High Risk or Low Risk Oral epithelial Dysplasia Not previously treated for leukoplakia Group III Healthy control participants Age and sex matched individuals No clinical evidence of oral potentially malignant disorders OPMD or OSCC No history of tobacco or areca nut use Willingness to participate Signed informed consent Willing to provide saliva samples and undergo oral examination
Exclusion criteria
Exclusion criteria: Individuals with other oral potentially malignant disorders like OSMF erythroplakia lichen planus Patients who have received treatment for OSCC or leukoplakia previously Presence of systemic illness like uncontrolled diabetes autoimmune diseases chronic infections Inadequate saliva sample like insufficient volume or degraded RNA Pregnant or lactating women due to hormonal influences on gene expression Individuals unwilling or unable to comply with study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This research will focus on an important public health problem in India of a persistent and incapacitating disease i.e. oral cancer and its predisposing premalignant state associated with habitual tobacco and areca nut useTimepoint: zero month six month one year | — |
Secondary
| Measure | Time frame |
|---|---|
| The concept of developing a noninvasive diagnostic gene expression panel of epithelial mesenchymal transition related transcriptomic genes in saliva for early detection , risk stratification & disease progression of oral leukoplakia & oral squamous cell carcinoma. Due to the potent role of EMT in the carcinogenesis, its evaluation may help in identification of high-risk lesions not diagnosed with routine histopathologic examinationTimepoint: Zero months six months one year | — |
Countries
India
Contacts
Public ContactDr Manjula M
KAHER KLE VKIDS
Outcome results
None listed